Prostate-specific antigen doubling time is a significant predictor of overall and disease-free survival in patients with prostate adenocarcinoma treated with brachytherapy. - Resende Salgado L; Rhome R; Oh W; Stone N; Stock R (Brachytherapy, 2018)